These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 6889190)

  • 21. Localized carcinoma of the prostate (stages T1B, T1C, T2, and T3). Review of management with external beam radiation therapy.
    Perez CA; Hanks GE; Leibel SA; Zietman AL; Fuks Z; Lee WR
    Cancer; 1993 Dec; 72(11):3156-73. PubMed ID: 7694785
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Stage D1 adenocarcinoma of prostate.
    Donohue RE; Mani JH; Whitesel JA; Mohr S; Scanavino D; Augspurger RR; Biber RJ; Fauver HE; Wettlaufer JN; Pfister RR
    Urology; 1984 Feb; 23(2):118-21. PubMed ID: 6695475
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland.
    Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
    Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):664-73. PubMed ID: 11849788
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of local control on metastatic dissemination in carcinoma of the prostate: long-term results in patients treated with 125I implantation.
    Fuks Z; Leibel SA; Wallner KE; Begg CB; Fair WR; Anderson LL; Hilaris BS; Whitmore WF
    Int J Radiat Oncol Biol Phys; 1991 Aug; 21(3):537-47. PubMed ID: 1869452
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Total prostatectomy for localized prostatic cancer.
    Gibbons RP; Correa RJ; Brannen GE; Mason JT
    J Urol; 1984 Jan; 131(1):73-6. PubMed ID: 6690752
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of clinically nonpalpable prostate-specific antigen-detected (cT1c) versus palpable (cT2) prostate cancers in patients undergoing radical retropubic prostatectomy.
    Ghavamian R; Blute ML; Bergstralh EJ; Slezak J; Zincke H
    Urology; 1999 Jul; 54(1):105-10. PubMed ID: 10414735
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Carcinoma of the prostate: clinical and pathological staging and prognosis.
    Gibbons RP; Elder JS; Wheelis RF; Correa RJ; Brannen GE
    Prostate; 1983; 4(5):441-6. PubMed ID: 6889189
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Survival of patients with localized prostate cancer treated with percutaneous transperineal placement of radioactive gold seeds: stages A2, B, and C.
    Hochstetler JA; Kreder KJ; Brown CK; Loening SA
    Prostate; 1995 Jun; 26(6):316-24. PubMed ID: 7784271
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of radical prostatectomy for stage A2 carcinoma of the prostate.
    Elder JS; Gibbons RP; Correa RJ; Brannen GE
    Cancer; 1985 Nov; 56(9):2151-4. PubMed ID: 4052963
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 prostate cancer: results from the SEARCH database.
    Freedland SJ; Presti JC; Terris MK; Kane CJ; Aronson WJ; Dorey F; Amling CL;
    J Urol; 2003 Jun; 169(6):2129-35. PubMed ID: 12771734
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 125I implantation for carcinoma of prostate. Further follow-up of first 100 cases.
    Grossman HB; Batata M; Hilaris B; Whitmore WF
    Urology; 1982 Dec; 20(6):591-8. PubMed ID: 7179624
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Morbidity and mortality of local failure after definitive therapy for prostate cancer.
    Schellhammer PF; Whitmore RB; Kuban DA; el-Mahdi AM; Ladaga LA
    J Urol; 1989 Mar; 141(3):567-71. PubMed ID: 2918594
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expectant management of clinically localized prostatic cancer.
    Warner J; Whitmore WF
    J Urol; 1994 Nov; 152(5 Pt 2):1761-5. PubMed ID: 7933234
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Cancer of the prostate: results of radiotherapy. Multicenter study].
    Allain YM; Bolla M; Douchez J; Gary-Bobo J; Geslin J; Huart J; Mathieu G; Mazeron JJ
    Bull Cancer; 1985; 72(6):559-67. PubMed ID: 3912017
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pathological stage is higher in older men with clinical stage B1 adenocarcinoma of the prostate.
    Alexander RB; Maguire MG; Epstein JI; Walsh PC
    J Urol; 1989 Apr; 141(4):880-2. PubMed ID: 2926881
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Competing risk analysis after radical prostatectomy for clinically nonmetastatic prostate adenocarcinoma according to clinical Gleason score and patient age.
    Sweat SD; Bergstralh EJ; Slezak J; Blute ML; Zincke H
    J Urol; 2002 Aug; 168(2):525-9. PubMed ID: 12131302
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The patient, disease status, and treatment options for prostate cancer: stages D1 and D2.
    Schmidt JD
    Prostate; 1983; 4(5):493-501. PubMed ID: 6351040
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
    Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
    J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The role of prostate-specific antigen in the diagnosis and treatment of prostatic adenocarcinoma].
    Stamey TA
    Urologe A; 1990 Mar; 29(2):52-64. PubMed ID: 1691883
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality.
    Kollmeier MA; Stock RG; Stone N
    Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):645-53. PubMed ID: 14529768
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.